BT-11 has the Potential to Exert Anti-Inflammatory Effects within the Gastrointestinal Track
BT-11, our lead product candidate, is a first-in-class, gut-restricted oral therapeutic candidate that targets LANCL2, a membrane receptor that has been shown to modulate immunological mechanisms that are associated with the autoimmune diseases: ulcerative colitis (UC) and Crohn’s disease (CD). Based on clinical data to date, BT-11 may address the main limitations of current therapies with a convenient once a day dosing that offers low systemic exposure, improved tolerability and no ties to toxicities.
Landos is currently conducting a Phase 2 trial of BT-11 in patients affected by mild to moderate UC in the U.S. EU and Russia and expects to report topline data in the second half of 2020.
Landos expects to conduct a Phase 2 trial in patients affected by moderate to severe CD in the first half of 2021.
